Back

The role of TTR as a surrogate marker in treatment of ATTR-CM

2 September 2024 (10:20 - 10:30)
Organised by: Logo
Congress Presentation Part of: What is the role of TTR in transthyretin amyloid cardiomyopathy? Cardiomyopathies Open Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Julian Gillmore

UCL, Greater London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Introduction
Doctor M. Maurer (New York, US)
Slides Video
Presentation thumbnail
The role of TTR in ATTR-CM disease and treatment
Professor T. Damy (Creteil, FR)
Slides Video
Presentation thumbnail
Question & answers
Presentation thumbnail
Questions & answers
Presentation thumbnail
Summary, audience Q&A, panel discussion and closing of session
Professor T. Damy (Creteil, FR) Doctor M. Maurer (New York, US) Doctor J. Gillmore (Greater London, GB)
Slides Video

Access the full session

Session thumbnail
What is the role of TTR in transthyretin amyloid cardiomyopathy?
Video

The Event

Event poster

ESC Congress 2024

2 September 2024 10:20 CET
You may be interested in
thumbnail
Congress Session
Treatment of transthyretin amyloidosis cardiomyopathy: on the path to a cure?
30 August 2025
thumbnail
Congress Presentation
Beyond stability: unveiling the prognostic and therapeutic role of serum transthyretin in amyloid cardiomyopathy
31 August 2025
thumbnail
Congress Presentation
Insights on the value of biomarkers in the management of transthyretin amyloid cardiomyopathy (ATTR-CM)
28 August 2023
thumbnail
Congress Presentation
Acoramidis improves serum TTR levels in patients with wild-type or variant transthyretin amyloid cardiomyopathy - results from ATTRibute-CM
20 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources